Cigna Group (CI) is a "clear standout" in the volatile health-care insurance industry, thanks in part to a "diversified and stable earnings flow," Oppenheimer said Friday in a report.
"The company's service-based platform leaves minimal exposure to risk-products that are igniting volatility across the managed care space," Oppenheimer said.
Cigna's Evernorth division has been capitalizing on surging demand for GLP-1 medications to treat Type 2 diabetes and obesity, starting programs that cap out-of-pocket costs and streamline access, the report said.
Cigna "remains one of the most attractive stocks to own" with "an attractive portfolio that should yield solid growth," the report said.
Oppenheimer reiterated its outperform rating on Cigna stock and price target of $375.
Price: 314.71, Change: +0.31, Percent Change: +0.10
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。